Advertisement
UK markets open in 30 minutes

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,175.54
    +346.61 (+2.06%)
     

  • CRUDE OIL

    83.52
    +0.16 (+0.19%)
     

  • GOLD FUTURES

    2,341.20
    -0.90 (-0.04%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,543.65
    +6.52 (+0.01%)
     

  • CMC Crypto 200

    1,415.06
    -9.04 (-0.63%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Merck KGaA expects 2023 profit to slip as COVID demand wanes

Ludwig Burger
Updated ·2-min read
A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt

By Ludwig Burger

FRANKFURT (Reuters) - Germany's Merck KGaA on Thursday predicted 2023 earnings would slip due to a decline at its electronic chemicals unit and a drop in COVID-related demand for its lab supplies from drug and vaccine makers.

For 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, the company "assumes a moderate decline to an about stable development", before any currency swings, it said in a statement.

Negative foreign exchange effects would likely be an additional drag of between 1% and 4%, according to the maker of pharmaceuticals, lab equipment and specialty chemicals.

ADVERTISEMENT

"Overall, Merck assumes that 2023 will be a challenging year. The slowing semiconductor market, decreasing Covid-19-related demand and persistently high inflation will contribute to this," the family-controlled group said in a statement.

Revenues from COVID-19 related lab supplies would likely drop to 250 million euros from 800 million last year, it added.

Pharmaceutical companies such as Pfizer, Moderna, Gilead and Roche have this year warned of a plunge in pandemic-related product sales after making billions from them over the past two years.

Still, Merck Chief Executive Belen Garijo upheld the German group's goal of 25 billion euros ($26.6 billion) in sales by 2025, up from 22.2 billion last year, citing new product development and a diversified business.

Analysts have said that two important trial results, expected at the end of the year, could boost longer-term earnings prospects at Merck's drug business.

One is on a next-generation multiple sclerosis drug candidate, where Merck is ahead in a development race with Novartis, Sanofi and Roche, and the other on an experimental head and neck cancer drug known as xevinapant.

Merck also reported fourth-quarter adjusted EBITDA rose 11% to 1.63 billion euros, slightly short of the average estimate of 1.69 billion euros in an analyst poll on the company's website.

($1 = 0.9401 euros)

(Reporting by Ludwig Burger, Editing by Friederike Heine and Kim Coghill)